1-3 of 3
Karl Egerer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Christian Jakob, MD, Peter Liebisch, MD, Karl Egerer, MD, Jan Sterz, MD, Martin Kaiser, MD, Susanne Rötzer, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Peter M. Kloetzel, PhD, Evangelos Terpos, MD, Orhan Sezer, MD
Journal: Blood
Blood (2007) 110 (11): 1475.
https://doi.org/10.1182/blood.V110.11.1475.1475
Published: 2007
Journal Articles

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Clinical Trials & Observations
Christian Jakob, Karl Egerer, Peter Liebisch, Seval Türkmen, Ivana Zavrski, Ulrike Kuckelkorn, Ulrike Heider, Martin Kaiser, Claudia Fleissner, Jan Sterz, Lorenz Kleeberg, Eugen Feist, Gerd-R. Burmester, Peter-M. Kloetzel, Orhan Sezer
Journal: Blood
Blood (2006) 109 (5): 2100–2105.
https://doi.org/10.1182/blood-2006-04-016360
Published: 2006
Journal Articles

Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma.

Christian Jakob, MD, Karl Egerer, PhD, Eugen Feist, MD, Ivana Zavrski, MD, Jan Eucker, MD, Ulrike Heider, MD, Gerd Burmester, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD
Journal: Blood
Blood (2004) 104 (11): 1486.
https://doi.org/10.1182/blood.V104.11.1486.1486
Published: 2004